Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Gains from Sales and Divestitures (2022 - 2023)

Cytek Biosciences' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $260297.0 for Q2 2023.

  • For Q2 2023, Gains from Sales and Divestitures rose 238.09% year-over-year to $260297.0; the TTM value through Jun 2023 reached $260297.0, up 238.09%, while the annual FY2022 figure was $215433.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $260297.0 in Q2 2023 per CTKB's latest filing, up from $81639.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $260297.0 in Q2 2023 to a low of $76990.0 in Q2 2022.